All In Biotech

Drug Trial Radar · NCT05477524

An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)

A PHASE 3, MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED TRIAL TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, IMMUNOGENICITY, AND LOT CONSISTENCY OF A 6-VALENT OSPA-BASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS ≥5 YEARS OF AGE

Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 12,546 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

12,546

Actual

Start

Aug 4, 2022

Primary completion

Jan 7, 2026

Study completion Jan 7, 2026

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
Valneva Austria GmbH
First posted
Jul 28, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this clinical study is to evaluate a 6-valent OspA-based Lyme disease vaccine (VLA15) for prevention of Lyme disease within North America and Europe. Approximately 9,400 healthy participants (this number excludes participants from 8 sites which were terminated for quality issues) 5 years and older will be recruited from areas with high levels of endemic Lyme disease to receive VLA15 or placebo (an inactive substance consisting of saltwater). Each participant will have about a 50% chance of receiving VLA15 and about a 50% chance of receiving placebo. A subset of participants will receive VLA15 from 3 different lots or placebo (1:1:1:3 ratio) to assess lot equivalence. Participants will receive a 3-dose primary vaccination series at about 0, 2, and 5 to 9 months and then receive a booster dose about 12 months after end of primary vaccination series. Vaccination of participants will occur at a time of year such that the primary series is completed before the peak Lyme disease season followed by a booster dose just prior to the beginning of the second Lyme disease season. A subset of participants will be followed for a third Lyme disease season. Comparison will be made between the Lyme disease cases of people receiving the study vaccine to those of the people who are not. This will help us determine if the study vaccine is safe and effective. If enrolled, participants will need to visit the research site at least 7 times during the study, and for a subset of participants up to 9 times. There will also be at least 5 telephone contacts. It is expected that each participant will take part in this study for up to about 2 and a half years. The subset of participants followed for a third Lyme disease season will take part in this study for up to about to 3 and a half years.

Conditions

  • Lyme Disease

Interventions

  • VLA15Biological

    Shot in the deltoid muscle (preferable in the nondominant arm)

  • SalineOther

    Shot in the deltoid muscle (preferable in the nondominant arm)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative incidence rate reduction of confirmed Lyme disease cases in the VLA15 group compared to the placebo groupTime frame: Beginning 1 month after receiving the booster dose (28 days after receiving the booster dose through the end of the Lyme disease season following the booster dose (end of October)).
  2. Percentage of participants reporting local reactionsTime frame: Within 7 days following each study intervention administration
  3. Percentage of participants reporting systemic eventsTime frame: Within 7 days following each study intervention administration
  4. Percentage of participants reporting adverse events (AEs)Time frame: Through 1 month following each study intervention administration
  5. Percentage of participants reporting newly diagnosed chronic medical conditions (NDCMCs)Time frame: Through study completion, up to approximately 42 months.
  6. Percentage of participants reporting serious adverse events (SAEs)Time frame: Through study completion, up to approximately 42 months.
  7. Geometric mean ratio (GMR) of anti-OspA titers for each serotype (ST1-ST6) for Lot 1 to Lot 2Time frame: At 1 month after completion of the primary series and the booster dose
  8. Geometric mean ratio (GMR) of anti-OspA titers for each serotype (ST1-ST6) for Lot 1 to Lot 3Time frame: At 1 month after completion of the primary series and the booster dose
  9. Geometric mean ratio (GMR) of anti-OspA titers for each serotype (ST1-ST6) for Lot 2 to Lot 3Time frame: At 1 month after completion of the primary series and the booster dose
  10. Geometric mean ratio (GMR) of anti-OspA titers for each serotype (ST1-ST6)Time frame: At 1 month after completion of the booster dose
  11. Sero-response of anti-OspA IgG concentrations for each serotype (ST1-ST6)Time frame: At 1 month after completion of the booster dose

Locations

129 sites in 7 countries. Site status is shown where the registry gives one.

  • Care Access - Essex

    Essex, Connecticut

  • Care Access Mobile Site

    Ledyard Center, Connecticut

  • Care Access Mobile Site

    New London, Connecticut

  • Stamford Health Medical Group

    Stamford, Connecticut

  • Stamford Hospital

    Stamford, Connecticut

  • Northern Light Eastern Maine Medical Center

    Bangor, Maine

  • Care Access - Farmington

    Farmington, Maine

  • MaineHealth Pen Bay Hospital

    Rockport, Maine

  • Johns Hopkins

    Baltimore, Maryland

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Johns Hopkins Rockland Physician Practice and Research Group

    Lutherville, Maryland

  • Sumit Bhutani MD LLC

    Westminster, Maryland

  • Woodholme Gastroenterology Associates

    Westminster, Maryland

  • Pediatric Associates of Fall River

    Fall River, Massachusetts

  • Care Access - Lakeville

    Lakeville, Massachusetts

  • Care Access - Melrose

    Melrose, Massachusetts

  • ActivMed Practices and Research

    Methuen, Massachusetts

  • Care Access - Briarpatch and Mobile Site

    Nantucket, Massachusetts

  • Care Access - Nantucket

    Nantucket, Massachusetts

  • Care Access Mobile Site

    Nantucket, Massachusetts

  • South Shore Medical Center

    Norwell, Massachusetts

  • Care Access Mobile Site

    Oak Bluffs, Massachusetts

  • Care Access - Hingham

    Rockland, Massachusetts

  • Care Access Mobile Site

    Sandwich, Massachusetts

  • Sisu BHR

    Springfield, Massachusetts

  • Care Access Mobile Site

    Vineyard Haven, Massachusetts

  • Care Access - Wareham

    Wareham, Massachusetts

  • South Shore Hospital

    Weymouth, Massachusetts

  • University of Massachusetts Chan Medical School

    Worcester, Massachusetts

  • Clinical Research Institute

    Minneapolis, Minnesota

  • Care Access - Londonderry

    Londonderry, New Hampshire

  • Care Access - North Conway

    North Conway, New Hampshire

  • ActivMed Practices & Research, LLC.

    Portsmouth, New Hampshire

  • Internal Medicine Associates

    Bridgeton, New Jersey

  • Clinilabs

    Eatontown, New Jersey

  • Hunterdon Infectious Disease Specialists

    Flemington, New Jersey

  • Hunterdon Medical Center

    Flemington, New Jersey

  • Care Access - Hoboken

    Hoboken, New Jersey

  • IMA Clinical Research Warren

    Warren Township, New Jersey

  • Velocity Clinical Research, Binghamton

    Binghamton, New York

Showing 40 of 129 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.